Gilead and Xilio recently announced an exclusive license agreement to develop and commercialize Xilio’s XTX301, a Phase 1 tumor-activated IL-12 program. Waltham, Massachusetts-based Xilio Therapeutics is a clinical-stage biotechnology company that is developing tumor-activated immuno-oncology therapies. It is using a tumor-activated platform to build tumor-activated molecules, including antibodies, cytokines, bispecifics and cell engagers. Each of…